MedTrace Logo

Pharmacokinetics, Efficacy and Safety Assessment of T2345 Compared With Active Comparator in Newly Diagnosed Patients With Open-angle Glaucoma or Ocular Hypertension

NCT01494753 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2024-02-07

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to assess the pharmacokinetics, efficacy and safety of T2345 versus an active comparator.

Conditions

  • Primary Open Angle Glaucoma

Interventions

DRUG

T2345

One drop at 8.00pm.

DRUG

Prostaglandin

One drop at 8.00pm.

Sponsors & Collaborators

  • Laboratoires Thea

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-06-30
Primary Completion
2008-12-31
Completion
2008-12-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01494753 on ClinicalTrials.gov